Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AbCellera BiologicsABCL +3.60%53 Days Sales Outstanding is 623.63 as of Jun. 2026, which is 256% above its 10-year median of 175.20. GuruFocus rates ABCL with a GF Score™ of 53/100 and a GF Value™ of $4.87 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 839 Biotechnology companies, AbCellera Biologics ranks worse than 88.32% on this metric.
AbCellera Biologics (NAS:ABCL) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
AbCellera Biologics Days Sales Outstanding Related Terms
AbCellera Biologics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABCL vs ANAB, MLTX, SRPT: Days Sales Outstanding Comparison
For the Biotechnology subindustry, AbCellera Biologics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Days Sales Outstanding falls into.
AbCellera Biologics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 623.63 mean?
AbCellera Biologics (ABCL) has a Days Sales Outstanding of 623.63 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on AbCellera Biologics and its competitors. This is 256% above median its historical median of 175.20. Over the past decade, AbCellera Biologics' Days Sales Outstanding has ranged from 24.63 to 406.40. According to the industry distribution chart, AbCellera Biologics ranks #741 out of 839 companies in the Biotechnology industry, placing it in the top 88.3%.
Is AbCellera Biologics' Days Sales Outstanding too high?
AbCellera Biologics' current Days Sales Outstanding of 623.63 is 256% above median its 10-year median of 175.20. Over the past 10 years, this metric has ranged from a low of 24.63 to a high of 406.40. The Biotechnology industry median Days Sales Outstanding is 69.33. AbCellera Biologics' value of 623.63 is 799.5% above this industry median. Based on the distribution chart, AbCellera Biologics ranks #741 out of 839 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AbCellera Biologics has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Days Sales Outstanding compare to ANAB and MLTX?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #741 out of 839 companies for Days Sales Outstanding. This places AbCellera Biologics in the lower half of its industry. The industry median Days Sales Outstanding is 69.33. AbCellera Biologics' value of 623.63 is 799.5% above this benchmark. Historically, AbCellera Biologics' own Days Sales Outstanding has ranged from 24.63 to 406.40 over the past decade. While the company's 10-year median is 175.20 vs. the industry median of 69.33, AbCellera Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.33, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbCellera Biologics's current Days Sales Outstanding of 623.63 is 799.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on AbCellera Biologics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current Days Sales Outstanding is 623.63, which is 256% above median its own 10-year median of 175.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.87, compared to a current price of $11.38 — trading 133.7% above its estimated fair value. The current Days Sales Outstanding is 623.63, which is 256% above median its 10-year median of 175.20 and 799.5% above the Biotechnology industry median of 69.33. AbCellera Biologics' overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Days Sales Outstanding is 623.63 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $11.38 is trading 133.7% above its estimated GF Value™ of $4.87.
GuruFocus considers AbCellera Biologics to be Significantly Overvalued.
Key valuation signals for ABCL:
Days Sales Outstanding: 623.63 (256% above median its 10-year median of 175.20)
GF Value™: $4.87 vs. price of $11.38 (133.7% above fair value)
Industry Position: 799.5% above the Biotechnology median (#741 of 839)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
53GF Score
Get the complete analysis for ABCL
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
